Entera Bio

ENTX

Market cap $61M

Entera Bio Ltd. (ENTX) Discusses Osteoporosis Treatment Landscape and Clinical Potential of EB613 Oral Tablet Transcript

In a virtual Key Opinion Leader (KOL) roundtable hosted today, Entera Bio (Nasdaq: ENTX) convened globally recognized authorities in osteoporosis and women's health to discuss the current osteoporosis treatment landscape and the opportunity for its lead clinical candidate, EB613 - being developed as the first and only oral anabolic (bone-forming) tablet for osteoporosis.

TEL AVIV, Israel, April 14, 2026 (GLOBE NEWSWIRE) -- TEL AVIV, Israel, April 14, 2026 -- Entera Bio Ltd. (Nasdaq: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced it will host a virtual Key Opinion Leader (KOL) webinar focused on the osteoporosis treatment landscape and the opportunity for its lead clinical candidate, EB613 (oral PTH (1-34) tablet), on Monday, April 20, 2026 at 11:00 AM Eastern Time.

MIAMI, April 6, 2026 /PRNewswire/ -- Global law firm Greenberg Traurig, P.A. advised Israel-based Entera Bio Ltd.

TEL AVIV, Israel, April 02, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX) (“Entera” or the “Company”), a leader in the development of oral peptides, today announced that it has entered into a securities purchase agreement for a private placement (the “Private Placement”) led by funds affiliated with BVF Partners L.P. (“BVF”).

U.S. stock futures rose on Monday following Friday's sharp sell-off. Futures of the major benchmark indices were higher after they entered the correction territory last week, falling more than 10% below their 52-week highs.

EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – FDA Type A endpoint alignment in July 2025, Phase 3 protocol submitted to the FDA with comments expected in early Q2 2026

Phase 3 study designed with total hip BMD primary endpoint assessed at 12 months, rather than at 24 months EB613 single tablet final commercial formulation (Next-Gen EB613) replaces multi-tablet EB613 as Phase 3 candidate, following successful bridging study Topline data anticipated in the second half of 2028, approximately one year earlier than previously expected; Entera commits to a 12-month extension study to run in parallel with potential NDA review TEL AVIV, March 04, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, today announced the submission to the U.S. Food and Drug Administration (FDA) of a clinical amendment providing a streamlined Phase 3 protocol, statistical analysis plan (SAP), and open-label extension synopsis to the Company's Investigational New Drug (IND) 505(b)(2) submission, to evaluate EB613 (Oral PTH(1-34), teriparatide).

TEL AVIV, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the development of oral peptide and protein replacement therapies, today announced that several members of its Board of Directors, including the Company's Chairman, have made open market purchases of the Company's ordinary shares. These transactions follow an earlier open market purchase by Entera Bio's Chief Executive Officer, Miranda Toledano, in December 2025.

New Chairman Joins Entera's Board with Senior Global Leadership Experience from Pfizer, Wyeth and Other Leading Biopharma Companies as Entera Advances Multiple Oral Peptide Programs Toward Significant Milestones in 2026 New Chairman Joins Entera's Board with Senior Global Leadership Experience from Pfizer, Wyeth and Other Leading Biopharma Companies as Entera Advances Multiple Oral Peptide Programs Toward Significant Milestones in 2026